Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.

Area of Science:

• Genetics
• Dermatology
• Molecular Biology

Background:

• Epidermolysis bullosa (EB) is a severe monogenetic skin disease characterized by extreme blistering and lesions due to genetic mutations affecting skin proteins.
• These mutations impair the dermal-epidermal junction, causing significant patient burden and driving the need for advanced therapies.

Purpose of the Study:

• To review the current landscape of gene therapy approaches for epidermolysis bullosa.
• To highlight recent breakthroughs and promising therapeutic strategies for EB.

Main Methods:

• Gene replacement therapy: successful application in severe EB forms.
• Gene editing technologies: advancements in designer nucleases for precise mutation repair.

Main Results:

• Beremagene geperpavec (B-VEC), a gene replacement therapy, has been approved by the FDA for severe EB.
• Gene editing technologies show potential for efficient and permanent mutation repair in EB.

Conclusions:

• Gene therapy, including gene replacement and editing, is rapidly advancing the treatment of epidermolysis bullosa.
• These genomic-level interventions offer promising curative outcomes for patients with this severe genetic skin condition.